Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at Leerink Swann boosted their Q3 2017 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research report issued on Wednesday. Leerink Swann analyst J. Schwartz now anticipates that the biotechnology company will post earnings of ($1.17) per share for the quarter, up from their prior forecast of ($1.29). Leerink Swann has a “Buy” rating and a $60.00 price objective on the stock. Leerink Swann also issued estimates for Sarepta Therapeutics’ Q4 2017 earnings at ($0.56) EPS, FY2017 earnings at ($3.71) EPS and FY2018 earnings at ($1.14) EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. The business’s quarterly revenue was up 350000.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.19) EPS. TRADEMARK VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/08/q3-2017-eps-estimates-for-sarepta-therapeutics-inc-raised-by-analyst-srpt.html.

Several other equities research analysts have also commented on the company. SunTrust Banks, Inc. reiterated a “buy” rating and set a $56.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Thursday. Piper Jaffray Companies reiterated an “overweight” rating and set a $55.00 price objective (up from $50.00) on shares of Sarepta Therapeutics in a research note on Thursday. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday. Finally, Credit Suisse Group boosted their price objective on Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an “outperform” rating in a research note on Thursday. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $62.31.

Sarepta Therapeutics (NASDAQ:SRPT) opened at 45.38 on Friday. The stock’s market cap is $2.92 billion. The firm’s 50-day moving average price is $39.28 and its 200 day moving average price is $34.10. Sarepta Therapeutics has a 12-month low of $25.47 and a 12-month high of $63.73.

In other Sarepta Therapeutics news, Director Edward M. Md Kaye sold 10,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $410,000.00. Following the transaction, the director now owns 62,471 shares of the company’s stock, valued at $2,561,311. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Shamim Ruff sold 12,138 shares of the firm’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $42.97, for a total value of $521,569.86. Following the transaction, the senior vice president now directly owns 27,312 shares in the company, valued at approximately $1,173,596.64. The disclosure for this sale can be found here. Insiders sold 78,056 shares of company stock worth $3,224,208 in the last three months. 9.60% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Asymmetry Capital Management L.P. grew its holdings in shares of Sarepta Therapeutics by 82.2% during the second quarter. Asymmetry Capital Management L.P. now owns 158,810 shares of the biotechnology company’s stock worth $5,353,000 after buying an additional 71,630 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Sarepta Therapeutics by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after buying an additional 271 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Sarepta Therapeutics by 85.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 20,871 shares of the biotechnology company’s stock worth $704,000 after buying an additional 9,635 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Sarepta Therapeutics by 3.7% during the second quarter. The Manufacturers Life Insurance Company now owns 40,188 shares of the biotechnology company’s stock worth $1,355,000 after buying an additional 1,435 shares during the last quarter. Finally, Osterweis Capital Management Inc. purchased a new position in shares of Sarepta Therapeutics during the second quarter worth about $3,806,000. 65.43% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.